Methods for detecting cardiac damage
AssigneeAcorda Therapeutics, Inc.
InventorsXinhua Yan, Anthony O. Caggiano
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designed to treat a damaged heart in a patient.
Claims16
A method for screening a population of patients to identify a subpopulation of patients exhibiting heart damage, the method comprising:
- detecting intracellular levels of cardiac troponin T (cTnT) or cardiac troponin I (cTnI) in cardiac tissue of a patient in the population, wherein a decrease in intracellular levels of either cTnT or cTnI in cardiac tissue of the patient relative to control or normal intracellular levels of either cTnT or cTnI, respectively, is indicative of heart damage and classifies the patient as a member of the subpopulation of patients exhibiting heart damage.
A method for diagnosing a patient suspected of having cardiac damage, the method comprising:
- detecting intracellular levels of cardiac troponin T (cTnT) or cardiac troponin I (cTnI) in cardiac tissue of the patient and comparing the intracellular levels of cTnT or cTnI in cardiac tissue detected for the patient to those of a control sample of cardiac tissue, wherein a decrease in intracellular levels of either cTnT or cTnI in cardiac tissue of the patient relative to those of the control sample of cardiac tissue is indicative of cardiac damage in the patient and identifies the patient as a candidate for therapeutic intervention to treat the heart damage.
A method for determining efficacy of a therapeutic regimen, the method comprising:
- a) detecting intracellular levels of cardiac troponin T (cTnT) or cardiac troponin I (cTnI) in cardiac tissue of a patient prior to initiation of the therapeutic regimen;
- b) detecting intracellular levels of cTnT or cTnI in cardiac tissue of the patient after initiation of the therapeutic regimen;
- and
Dependencies are inferred from the claim text.